Delving into the Latest Updates on Cetirizine Hydrochloride with Synapse

Overview

Basic Info

SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions.

Drug Type

Small molecule drug

Synonyms

Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride

+ [46]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Rhinitis, Allergic, SeasonalConjunctivitis, AllergicDermatitis+ [8]

Inactive Indication

Acute conjunctivitisChronic UrticariaDermatitis, Atopic+ [2]

Originator Organization

Johnson & Johnson

Active Organization

Teva UK Ltd.

Suzhou Dawnrays Pharmaceutical Co., Ltd.

UCB Japan Co. Ltd.

+ [7]

Inactive Organization

GSK Plc

McNeil AB

Nicox Ophthalmics, Inc.

+ [8]

License Organization

Apotex, Inc.ITROM Pharmaceutical Group

Santen Pharmaceutical Co., Ltd.

+ [12]

Drug Highest PhaseApproved

First Approval Date

Canada (31 Dec 1991),

Rhinitis, AllergicUrticaria

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC21H26Cl2N2O3

InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N

CAS Registry83881-52-1

Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.

Start Date11 Apr 2025

Sponsor / Collaborator

Zhejiang Hospital

CTRI/2024/08/072453

/ RecruitingPhase 3

A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL

Start Date20 Aug 2024

Sponsor / Collaborator

Akums Drugs & Pharmaceuticals Ltd.

[+1]

NCT06819774

/ RecruitingPhase 3

Efficacy and Safety of Cetirizine Hydrochloride Injection in the Treatment of Acute Urticaria: a Randomized, Double-blind, Positive Controlled, Multicenter Phase III Clinical Study

The objective of this study was to evaluate the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria.The participants were randomized to receive cetirizine hydrochloride or diphenhydramine hydrochloride.

Start Date22 Apr 2024

Sponsor / Collaborator

Shandong New Time Pharmaceutical Co. Ltd.

100 Clinical Results associated with Cetirizine Hydrochloride

Login to view more data

100 Translational Medicine associated with Cetirizine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Cetirizine Hydrochloride

Login to view more data

3,786

Literatures (Medical) associated with Cetirizine Hydrochloride

01 Aug 2025·FOOD CHEMISTRY

Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)

Article

Author: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming

This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.

03 Jul 2025·ANALYTICAL LETTERS

Development of Highly Sensitive Voltammetric Methods for the Determination of Antihistamine Drug Cetirizine Using A Poly(Bromocresol Purple) Film-Based Electrochemical Sensor

Author: Kul, Dilek ; Reis, Hamit Ali ; Sofu, Ümran ; Öztürk, Gökçe ; Erdemir, Fatih

Simple and highly sensitive voltammetric methods were developed using a poly(bromocresol purple) modified glassy carbon electrode to quantify cetirizine.Poly(bromocresol purple) film was synthesized on the surface of a glassy carbon electrode by cyclic voltammetry for 50 potential cycles in 0.1 M phosphate buffer at pH 6.0 containing 5.0 x 10-4 M of the monomer.Quantification of cetirizine exhibiting irreversible properties using the optimized conditions with a linear dependence between cetirizine concentration and peak currents from 0.2 to 100 μM for differential pulse voltammetry (DPV) and 0.1 to 100 μM for square wave voltammetry (SWV).Detection limits were 21.8 and 15.1 nM for DPV and SWV, resp.Relative standard deviation (RSD) values below 0.98% indicated good precision.Recovery values from 100.12% to 100.90% with relative standard deviations below 1.14% for DPV and SWV in pharmaceutical formulations and urine samples demonstrated the high accuracy of the developed methods.The prepared modified electrode exhibited good fabrication reproducibility and suitable long-term stability.Finally, no interferences were observed in cetirizine determination in the presence of co-existing substances in the biol. samples.

01 Jul 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice

Article

Author: Sasaki, Akiko ; Baba, Yuta ; Yoshimura, Kiyoshi ; Tsunoda, Takuya ; Shimane, Toshikazu ; Nakashima, Rie ; Maruyama, Yuki ; Sasaki, Aya ; Shida, Midori ; Kuramasu, Atsuo ; Tsuji, Mayumi ; Toyoda, Hitoshi ; Tsurui, Toshiaki ; Hosonuma, Masahiro ; Funayama, Eiji ; Tajima, Kohei ; Kiuchi, Yuji

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited in inflammation-associated tumors, necessitating combinatorial approaches. Although combinations with cytotoxic or targeted agents are well established, the therapeutic potential of non-oncologic drugs, such as antihistamines, is less explored. In this study, we investigate whether cetirizine, a non-sedating histamine H₁ receptor antagonist, enhances the antitumor effects of anti-programmed cell death protein 1 (PD-1) antibody in a murine model of colitis-associated colorectal cancer. Combination therapy, not monotherapy, significantly reduced tumor volume in vivo. Flow cytometry of splenocytes revealed increased PD-1 expression on T cells only in the combination group, suggesting systemic immune activation. Immunohistochemical analysis showed elevated CD3⁺ T-cell infiltration into tumors following combination treatment. Meanwhile, gene expression analysis of tumor tissues revealed downregulated Vegfa, Mmp9, Il10, and Cd80, along with upregulated Hspg2 and Fn1, suggesting a shift in the tumor microenvironment. In vitro, cetirizine suppressed Mmp9 expression in CT26 cells, Il10 in macrophages, and VEGFA in human umbilical vein endothelial cells, indicating cell-type-specific effects that partially mirror the in vivo findings. Immunohistochemistry further demonstrated a reduced frequency of FoxP3⁺ regulatory T cells among CD3⁺ T cells within the tumor stroma in the combination group. Collectively, these findings indicate that cetirizine enhances ICI efficacy by reshaping the tumor microenvironment through immunomodulatory mechanisms. Our results support the repurposing of antihistamines as a novel strategy to improve cancer immunotherapy.

123

News (Medical) associated with Cetirizine Hydrochloride

27 May 2025

·www.einpresswire.com

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan Milestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025 Extends Nicox’s cash runway until the end of 2025 May 27, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner for NCX 470, Kowa, has received Clinical Trial Notification (equivalent of a U.S. Investigational New Drug, IND) approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan, triggering a €1 million milestone payment to Nicox. The clinical trials are expected to be initiated in H2 2025, which would trigger a second milestone payment of €2 million. “ This important achievement, which enables the initiation of phase 3 clinical development of NCX 470 for Japanese patients, demonstrates the effective collaboration established between the Kowa and Nicox teams and represents a significant advance by Kowa in the delivery of their accelerated development plan. As a result, we expect to receive a total of €3 million in development milestones from Kowa in 2025, extending our cash runway until at least the end of 2025 . ” said Gavin Spencer, Chief Executive Officer of Nicox. “ We congratulate our Japanese partner on the swift progress and look forward to continuing to work with them to bring NCX 470 to the Japanese market. ” Cash Runway Based on the current cash position, estimated revenue and anticipated milestone payments (including the Kowa milestones mentioned above) Nicox now estimates that it is financed until the end of 2025. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. Key Future Milestones Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: Topline results are expected in the third quarter of 2025 NCX 470 Phase 3 clinical trial in Japan: Initiation expected in H2 2025 Kowa NCX 470 License Nicox licensed the rights to develop and commercialize NCX 470 in Japan to Kowa in February 2024. Nicox may receive a further €7 million in development and regulatory milestones, up to €17.5 million in sales milestones and tiered royalties from 7% to 12% on net sales of NCX 470 in Japan. Kowa is responsible for all development, regulatory and commercialization costs for NCX 470 in Japan. About NCX 470 NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last American patient in Denali has completed their final visit, with Chinese patients completing theirs, and the results are expected in Q3 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China, where NCX 470 is exclusively licensed to Ocumension Therapeutics. NCX 470 is also licensed exclusively to Kowa for Japan. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverage H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2024 ” which is available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 Attachment EN_NCX470JapanINDApprovalMay2025_PR_FINAL Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 3

23 May 2025

·www.einpresswire.com

Cetirizine or Levocetirizine: Drug Safety Communication - FDA Warns About Risk of Severe Itching After Discontinuation of Long-Term Use of Allergy Medicines

AUDIENCE: Consumer, Patient, Health Care Professional, Pharmacy, Dermatology ISSUE: The FDA is warning that patients stopping the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) after long-term use may experience rare but severe itching. These medicines are available in prescription and over-the-counter (OTC) forms . The itching, also called pruritus, has been reported in patients who used these medicines daily, typically for at least a few months and often for years. Patients did not experience itching before starting the medicines. Reported cases were rare but sometimes serious, with patients experiencing widespread, severe itching that required medical intervention. As a result, we are revising the prescription cetirizine and levocetirizine prescribing information to include a new warning about this risk. We will subsequently request that manufacturers add a warning about pruritus to the Drug Facts Label of the OTC versions. BACKGROUND: Cetirizine and levocetirizine are antihistamines that block a molecule called histamine that the body releases during allergic reactions. Both medicines are approved to treat seasonal allergies, called seasonal allergic rhinitis, in adults and children 2 years and older. The medicines are also approved to treat year-round allergies, called perennial allergic rhinitis, and chronic hives, called chronic idiopathic urticaria, in patients 6 months and older. Cetirizine was approved for oral use by prescription in December 1995 under the trade name Zyrtec (no longer sold as a prescription medicine) and approved for OTC use in November 2007. Levocetirizine was approved for oral use by prescription in May 2007 under the trade name Xyzal and approved for OTC use in January 2017. RECOMMENDATIONS: Patients Contact your health care professional if you develop severe itching after stopping prescription or OTC cetirizine or levocetirizine. Patients should know that itching typically occurred within a few days of stopping these medicines after daily use for a few months to years. If you are planning on using cetirizine or levocetirizine long term, especially for more than a few months, should discuss the benefits and risks with your health care professional, who can provide advice based on your personal needs. Health Care Professionals Discuss the risk of pruritus after stopping cetirizine or levocetirizine with patients when prescribing or recommending these medicines, especially if planned for chronic use, and with those who indicate they are using OTC versions. Advise patients to contact you if they experience severe itching after stopping cetirizine or levocetirizine. [ FDA Safety Communication - 05/16/2025] Content current as of: 05/23/2025 Regulated Product(s) Topic(s) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalAccelerated ApprovalPatent Expiration

16 May 2025

·www.einpresswire.com

FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)

Between April 25, 2017, and July 6, 2023, FDA identified 209 cases worldwide (197 domestic) of pruritus after stopping treatment with cetirizine (n=180), levocetirizine (n=27), or both (n=2), in the FDA Adverse Event Reporting System (FAERS) database. In all 209 cases, there was a temporal relationship between discontinuing the medicine and the onset of pruritus, and the median time to onset was 2 days, with a range of 1 to 5 days. Of these reported cases, 87 percent (n=182) were submitted by individuals using the medicines, including 6 self-identified health care professionals reporting their symptoms. In nearly 92 percent (n=97) of the 106 pruritus cases where patients reported time length of medicine usage, the length was more than 3 months, suggesting this timeframe may be a risk predictor. The median duration of medicine use before pruritus occurrence after stopping cetirizine or levocetirizine was 33 months, with a range of 1 week to 23 years. The number of pruritus cases increased with duration of use, suggesting that longer use may increase the risk of this reaction. Many reports described post-discontinuation pruritus over many areas of the body that significantly affected users’ quality of life and ability to function. Serious outcomes included disability (n=48), such as “debilitating itching to the point of being bed-ridden,” hospitalization (n=3), and thoughts of suicide or self-harm (n=2). In 92 of the 93 cases where patients reported one or more attempts at restarting then stopping the medicine, pruritus recurrence occurred. Restarting the medicine resolved pruritus in 71/79 individuals (90 percent) and tapering off the medicine after restarting it resolved symptoms in 9/24 (38 percent) of those who tried this approach. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultClinical StudyDrug Approval

100 Deals associated with Cetirizine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00664	Cetirizine Hydrochloride	R06AE07	DB00341

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	United States	Harrow, Inc.	30 May 2017
Dermatitis	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Eczema	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Pruritus	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Anaphylaxis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Rhinitis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Chronic Urticaria	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Perennial	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Seasonal	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic	Canada	Pfizer Canada ULC	31 Dec 1991
Urticaria	Canada	Pfizer Canada ULC	31 Dec 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	NDA/BLA	South Korea	SAMIL PHARMACEUTICAL Co., Ltd.	-
Acute urticaria	Phase 3	United States	JDP Therapeutics LLC	01 Jul 2013
Acute urticaria	Phase 3	Canada	JDP Therapeutics LLC	01 Jul 2013
Acute conjunctivitis	Phase 3	United States	Nicox Ophthalmics, Inc.	01 Mar 2012
Dermatitis, Atopic	Phase 3	-	GSK Plc	01 Aug 2005
Dermatomycoses	Phase 3	-	GSK Plc	01 Aug 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06039137 (H1-Switch Study, Pubmed \| JCO Oncol Pract)	Not Applicable	-	-	Intravenous Clemastine	dxjbbtcjrs(gtctynzdbx) = ycabugtwsc tnjubszxrt (auyqyfppex, -3.4 to 1.1)	Positive	07 Jun 2024
				Oral Cetirizine	dxjbbtcjrs(gtctynzdbx) = gduxvmpncg tnjubszxrt (auyqyfppex, -3.4 to 1.1)
NCT02023164 (CTgov)	Phase 3	Acute urticaria	36	JDP-205 (Test Drug)	phgzoytimw(tnbrgmokhf) = xblcusixno fydlqxeqkc (htekyomawm, 0.61) View more	-	09 Feb 2024
				Diphenhydramine (Control)	phgzoytimw(tnbrgmokhf) = entvktcyjq fydlqxeqkc (htekyomawm, 0.89) View more
NCT02865018 (CTgov)	Phase 1/2	Neuromyelitis Optica	16	cetirizine	hmgmdichmm(edtyqmdfiy) = olnpgpgxhs criwfygrwk (equxcaomnn, 0.80) View more	-	07 Jun 2023
PRECEPT (ECTRIMS2022)	Phase 3	-	20	Cetirizine 10mg	eonoefozhs(uscfagxqhp) = vlgauagqpi ghgjqvxrzw (yulszoraoc )	Positive	12 Oct 2022
				Diphenhydramine 25mg	eonoefozhs(uscfagxqhp) = qwkxghufwu ghgjqvxrzw (yulszoraoc )
NCT04189588 (versus, CTgov)	Phase 2	Hypersensitivity \| Neoplasms	34	Cetirizine HCl 10 mg/mL+Paclitaxel+Rituximab (Cohort A)	rupryqqtlu = ilfymqkewf kutnnwsvyy (suxawbyofm, iywjilvzdb - hjwnafzcwt) View more	-	17 May 2022
				Paclitaxel+Diphenhydramine 50 mg/mL+Rituximab (Cohort B)	rupryqqtlu = xinntzcyiq kutnnwsvyy (suxawbyofm, lvctpatksz - unqwptsndi) View more
NCT04189588 (ASCO2021)	Phase 2	Hypersensitivity	34	IV cetirizine 10 mg	wrdhxkvcdp(onswmmqajm) = bxkcsgmmwk fpfvnjtosx (sicorzvatz ) View more	-	28 May 2021
				IV diphenhydramine 50 mg	wrdhxkvcdp(onswmmqajm) = lcxditphli fpfvnjtosx (sicorzvatz ) View more
NCT02935699 (Pubmed \| Ann Emerg Med)	Phase 3	Acute urticaria	262	Intravenous Cetirizine 10 mg	wxemtfuxji(gbdohloqop) = jyvpzozsmo cjyjopucnp (ojgnzhzfeb ) View more	Positive	08 Jul 2020
				Intravenous Diphenhydramine 50 mg	wxemtfuxji(gbdohloqop) = yjqwituvta cjyjopucnp (ojgnzhzfeb ) View more
NCT03192488 (CTgov)	Phase 4	Hypoxia	13	Cetirizine (Cetirizine and Hypoxia)	dmkatfqozk(ikzhiypfyb) = phkzkjdgdw ccwgvjjahr (khwzajrjvv, 1.92) View more	-	16 Jun 2020
				Placebo (Placebo and Hypoxia)	dmkatfqozk(ikzhiypfyb) = kkgfxzncxa ccwgvjjahr (khwzajrjvv, 2.87) View more
NCT02935699 (CTgov)	Phase 3	Acute urticaria	262	Test Drug (JDP-205) (Test Drug)	nbzkxxhkjf(xusfyhmccn) = ciezsyxvyx kxmgemlkvb (tzsrxuxeix, 0.944) View more	-	27 Nov 2019
				Diphenhydramine (Control)	nbzkxxhkjf(xusfyhmccn) = sydztrlxyi kxmgemlkvb (tzsrxuxeix, 0.984) View more
NCT01825655 (CTgov)	Phase 4	Pruritus	3	Cetirizine (Cetirizine)	wzgflqcdnt(rundjamruj) = udppbqtvxf irwkhtlquk (digaosivwo, jhirlbuakj - wdrehjcbvp) View more	-	11 Sep 2018
				Placebo or sugar pill (Sugar Pill)	ztgzhqsmqj(hiwkxcjoaj) = votadmeuir howljbskqj (uwxwatrgif, vphshaqzvb - lqtpbanxol) View more